anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Streptomyces avermitilis lacking branched-chain 2-oxo acid dehydrogenase activity and avermectin B O-methyltransferase activity is claimed. The strain is deposited as ATCC53692. The nonnatural avermectins produced by the strain are characteised by the presence of OH gps. at the C-5 position of the aglycone moiety and/or the C-3' and/or C-3" positions of the oleandrose. moieties. The obtd. cpds. are useful for the same purposes as known avermectins. They are highly active antiparasitic agents having partic. utility as anthelmintics, ectoparasiticides, insecticides and acaricides.
The utility model discloses a Chinese herbal medicine channel-following massage stick, which consists of a mandrel, a barrel, a medicine layer and handle sleeves. Two ends of the mandrel are respectively provided with the handle sleeve, and the diameter of a handle sleeve hole is larger than that of the mandrel; the barrel is a cylinder with two ends being opened, the outer circular surface of the barrel cylinder is provided with 2 to 6 circles of convex rings, and each convex ring is provided with a plurality of small grooves; and the diameter of the mandrel is smaller than that of the hole of the barrel. The medicine layer is wound for one to two turns on the circumference of the barrel and is fixed by 2 to 6 bandages. The channel-following massage stick is applicable to the patients capable of suffering different stresses; and different medicine layers can be changed according to the disease situation and the disease part of the patient. Through double rotation of the mandrel, the barrel and the handle sleeves, the stress on the massage stick is uniform in the massage operation, so that the patient can feel comfortable. The convex rings are respectively provided with a small groove or patterns, so that the medicine layer is not easy to move, and the drugs can be reasonably dispensed. The channel-following massage stick is simple in structure of the medicine layer, low in production cost, convenient in use and  durable, and good in economic benefit and social benefit.
The invention relates to a medicated diet for treating infertility. The formula is prepared from the following active ingredients by weight: 20g of deer-horn glue, 120g of polished round-grained rice and 15g of gingers. The medicated diet is prepared by firstly cooking porridge with the polished round-grained rice, melting the deer-horn glue with wine, juicing the gingers and mixing the porridge with the deer-horn glue and the gingers after the porridge is boiled, thus obtaining the edible porridge. The medicated diet has the functions of invigorating the kidney and strengthening yang and replenishing essence and harmonizing the stomach. In the diet, deer-horn glue is used for warming yang and strengthening the Du meridian and nourishing yang in the kidney and is warm but not dry; the gingers are pungent and warm so as to improve the efficacy of the gingers; the polished round-grained rice has the functions of harmonizing the middle warmer and nourishing the stomach. The medicated diet has curative effects on infertility caused by kidney yang deficiency induced female dysmenorrhea and irregular menstruation as well as coldness of uteruses.
We have a three group randomized controlled design. Migraine patients from the headache outpatient clinic will randomly be assigned to get two different cover stories via a flyer with study information and through the physician from the outpatient clinic: 50% of patients will receive the information that they will take part to investigate migraine (by watching the visual stimulus (roller coaster video)). The other 50% will receive the information that they will take part as healthy controls for a headache unrelated study (by watching the visual stimulus (roller coaster video)). Sex and age matched healthy controls will take part in the same experiment and get no additional information but that we investigate the perception of a visual stimulus (roller coaster video). The protocol for the intervention is standardized and identical for all participants.

Migraine patients will be randomly given the priming information and therefore their group allocation. Physicians will allocate by pulling from a randomized equally sized stock of flyers (of which 50% inform for healthy controls and 50% for migraine patients).

Migraine Patients for both migraine groups will be recruited and diagnosed by a neurologist from the UKE headache outpatient clinic. Healthy controls will be recruited via an internet platform for job advertisement. Participants will be paid 10€ for participation. Participants must be at least 18 years old and have signed the informed consent. They are excluded if they have 1. History of any neurological disease, 2. Self-report of diagnosis of vestibular disease, 3. History of trauma or pathology of the cervical spine (e.g., whiplash associated disorder), 4. Pregnancy, 5. Other relevant musculoskeletal, systemic or psychiatric disease.
BACKGROUND: Therapeutic endoscopic procedures are increasingly necessary for children. Pediatric gastroenterologist training and experience with endoscopic hemostasis and other complex therapeutic endoscopy procedures are often limited. We evaluated the impact of the implementation of an advanced complex endoscopy (ACE) team, which provides 24/7 inpatient/outpatient back-up endoscopy support.
METHODS: We analyzed hemostasis quality outcomes in the 2 years before implementation of ACE (2018-2020) versus the year following the implementation of ACE (2020-2021). We analyzed pediatric gastroenterology provider satisfaction and perspectives with a survey that was distributed to faculty, fellows, and advanced practice providers 1 month before implementation of ACE and again 12 months following ACE implementation.
RESULTS: Endoscopy volume and outcome metrics for hemostasis procedures, including latency to endoscopy, need for reintervention, and administration/diversity of hemostatic therapy, including multimodal therapy, improved in the year following implementation of the ACE (p < 0.05 for each). Survey results demonstrated a positive impact on provider endoscopy experience and high utilization of ACE. Twenty-two percent of providers reported activating ACE in the prior month and 66% in the prior year. Most providers who activated ACE were very satisfied (85%) or satisfied (7.7%). Eighty-three percent noted ACE had a positive impact on inpatients, and 50% noted a positive impact on outpatient endoscopy. Provider anxiety with endoscopy diminished post-ACE implementation (62% vs. 28%). Respondents unanimously found ACE beneficial to patient care (100%).
CONCLUSIONS: ACE implementation was associated with improved provider perspectives surrounding endoscopy and significant improvement in hemostasis quality parameters, escalation of hemostasis procedure volume, and broadening the range of hemostasis interventions.
The invention discloses an eight-armed polyethylene glycol derivative (formula I), a preparation method and related biological substance modified by the eight-armed polyethylene glycol derivative. One quadrivalent group U and four tervalent groups Ec jointly form an octavalent central structure CORE0 high in symmetry, Lc is connected with octavalent center and eight polyethylene glycol arms and has polydispersity and monodispersity, and the polymerization degree of the Lc ranges fromm n1 to n8. The tail end of a single PEG chain is connected with at least one functional group F (k>=1). The PEG chain and the F can be disconnected (g=0) or can be connected with a tail end branching group G (g=1) through a divalent linking group L0, the tail end branching group G provides more reaction sites, enables the reaction sites to be combined with more medicine molecules, and drug loading capacity is improved. The eight-armed polyethylene glycol derivative is of a similar centrosymmetric structure, so that molecular weight control in the scale production is more accurate, and a product of narrow molecular weight distribution is easier to obtain. The performance of the related biological substance modified by the eight-armed polyethylene glycol derivative is more uniform and is easy to control.
BACKGROUND: Facial palsy after orthognathic surgery is an uncommon but serious complication causing dissatisfaction and affecting quality of life. The occurrence could be underreported. Surgeons need to recognize this issue regarding the incidence, causative mechanism, managements, and outcome.
METHODS: A retrospective review of orthognathic surgery records between January of 1981 and May of 2022 was conducted in the authors' craniofacial center. Patients who developed facial palsy after the surgery were identified, and demographics, surgical methods, radiologic images, and photographs were collected.
RESULTS: A total of 20,953 sagittal split ramus osteotomies (SSROs) were performed in 10,478 patients. Twenty-seven patients developed facial palsy, resulting in an incidence of 0.13% per SSRO. In a comparison of SSRO technique, the Obwegeser-Dal Pont technique using osteotome for splitting had higher risk of facial palsy than the Hunsuck technique using the manual twist splitting ( P < 0.05). The severity of facial palsy was complete in 55.6% of patients and incomplete in 44.4%. All patients were treated conservatively, and 88.9% attained full recovery in a median duration of 3 months [interquartile range (IQR), 2.75 to 6 months] after surgery, whereas 11.1% attained partial recovery. Initial severity of facial palsy predicted the timing of recovery, with incomplete palsy patients having faster median recovery (3 months; IQR, 2 to 3 months) than the complete palsy patients (6 months; IQR, 4 to 6.25 months) ( P = 0.02).
CONCLUSIONS: The incidence of facial palsy after orthognathic surgery was 0.13%. Intraoperative nerve compression was the most likely causative mechanism. Conservative treatment is the mainstay of therapeutic strategy, and full functional recovery was anticipated.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, IV.
The present invention belongs to the technical field of radiopharmaceutical chemistry, and provided are  18 F-labeled fluoropicolinylglycine as well as a preparation method therefor and an application thereof. The  18 F-labeled fluoropicolinylglycine provided in the present invention is 6-[ 18 F]-fluoro-3-picolinylglycine, 5-[ 18 F]-fluoro-2-picolinoylglycine, or 4-[ 18 F]-fluoro-2-picolinoylglycine. The  18 F-labeled fluoropicolinylglycine provided in the present invention has excellent stability and good biological properties, and has no adverse effects on an organism after decay. It may be known by means of an in vivo distribution test that the  18  F-labeled fluoropicolinylglycine is mainly absorbed by the kidneys and is then quickly discharged from the body. 10 min after injecting the  18 F-labeled fluoropicolinylglycine into the body of a mouse, almost all of same is discharged into the bladder. The  18 F-labeled fluoropicolinylglycine provided in the present invention is particularly advantageous for the evaluation of renal function in renal diseases.
Neonates with a history of in utero exposure to enalapril Maleate

If oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function. Enalapril, which crosses the placenta, has been removed from neonatal circulation by peritoneal dialysis with some clinical benefit, and theoretically may be removed by exchange transfusion, although there is no experience with the latter procedure.

Antihypertensive effects of enalapril maleate have been established in hypertensive pediatric patients age 1 month to 16 years. Use of enalapril maleate in these age groups is supported by evidence from adequate and well-controlled studies of enalapril maleate in pediatric and adult patients as well as by published literature in pediatric patients (see CLINICAL PHARMACOLOGY, Clinical Pharmacology in Pediatric Patients  and DOSAGE AND ADMINISTRATION).

Enalapril maleate is not recommended in neonates and in pediatric patients with glomerular filtration rate <30 mL/min/1.73 m2, as no data are available.
Gonadotropin-releasing hormone antagonist (GnRH-ant) cycles are characterized by higher patient acceptability with more attention being directed to the potential effect of steroid pretreatment to program antagonist protocol cycles, as marked size discrepancies of growing follicles reflect incoordinated maturation of follicular-oocyte complexes and complicates clinical criteria for human chorionic gonadotropin (hCG) administration. This phenomenon is associated with fewer mature oocytes and resulting embryos, which limits sufficient embryo selection for embryo transfer. Indeed, the large number of available embryos represented an important prognostic factor of invitro-fertilization (IVF) outcome, particularly in poor prognosis patients, possibly by increasing the probability that at least one good-quality embryo will be selected for embryo transfer. During COH, a better understanding of follicular development has resulted in the improvement of strategies for ovarian stimulation. This approach represents a potential and more physiological alternative to GnRH agonist or oral contraceptive pills pre-treatment in a trial to synchronize multi-follicular development and improve controlled ovarian hyperstimulation (COH) results. The present study is a randomized controlled trial that investigated whether E2 pre-treatment during the luteal phase affects developmental characteristics of growing follicles during COH. It depended on the hypothesis that growth asynchrony of antral follicles is a consequence of the gradual FSH elevation that occurs during the late luteal phase, thus testing for detection of the effect of luteal estradiol on follicular synchronization and its effect on ICSI outcome.
A tissue transfer method for reconstruction and augmentation of soft tissue. The method includes harvesting adipose tissue from a patient. The harvested tissue is processed via centrifugation to isolate a purified subset of the adipose tissue including separating and removing a substantial amount of triglycerides from the harvested adipose tissue. The centrifugation may be performed to cause separation of water from the purified adipose tissue and to cause separation of oil from mature adipocytes. Specifically, the spin rates may be selected to be high enough to cause lesions in the mature adipocytes that results in the release of the oil. The method continues with implanting the purified adipose tissue into the patient at a breast or other area identified for reconstruction or augmentation. The implanting is performed based on an injection pathway model that defines injection point locations and a number of injection pathway directions from each point.
Group will be subdivided into three subgroups according to their body mass index to normal, over weight and obese type1. All subjects will receive open chain exercises for rotator cuff muscles and advices for postural correction.
INTRODUCTION: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a frequent condition affecting approximately 2% of the population. Medical treatment consists long-term use of intranasal corticosteroids and short-term use of oral corticosteroids, in adjunct with saline solution rinses. Surgical management is proposed in patients who failed after medical treatment. In France, two biologics are reimbursed in case of severe uncontrolled CRSwNP despite medical treatment and endoscopic sinus surgery. Waiting for head-to-head biologics comparison, studies should report the efficacy and safety of biologics in large real-life cohorts. This study protocol describes the aims and methods of a prospective, observational, national, multicentric cohort of patients with CRSwNP treated with biologics.
METHODS AND ANALYSIS: The BIOlogics in severe nasal POlyposis SurvEy is a French multicentre prospective observational cohort study. The main aim is to assess the efficacy and tolerance of biologics in patients with CRSwNP, with or without association with other type 2 diseases, and to determine the strategies in case of uncontrolled disease under biologics. Patients over 18 years old requiring biologics for CRSwNP in accordance with its marketing approval in France (ie, severe nasal polyposis, with lack of control under nasal corticosteroid, systemic corticosteroids and surgery) are invited to participate. Collected data include topical history of surgical procedures and biologics, medication and use of systemic corticosteroids, visual analogical scales for specific symptoms, Sino-Nasal Outcome Test-22 questionnaire, nasal polyp score, asthma control test, Lund-Mackay score on CT scan and IgE concentration and eosinophilic count on blood sample.
TRIAL REGISTRATION: NCT05228041/DRI_2021/0030.
PURPOSE:The titled remedy containing an imidazoline derivative or a salt thereof as an active constituent. CONSTITUTION:A remedy for cerebral infarct containing a compound of the formula (R<1> is aryl; R<2> is halogen or lower alkyl which may be substituted by a halogen), e.g. 2-(2-phenoxy-5-chlorophenyl)amino-2-imidazoline. The remedy is capable of suppressing the onset of cerebral infarct, and improves the hematocytolytic ability. The above-mentioned remedy can be orally or parenterally administered, and the dosage form may be a tablet, powder, capsule, fine granule, syrup, suppository, injection, etc. The dose thereof is 1mg-5g/day, preferably 1-500mg/day expressed in terms of the compound of the formula or a salt thereof, and administered 1-4 times a day.
Teratogenic Effects. Pregnancy Category C   
Pregnancy Category C: Ketorolac tromethamine, administered during organogenesis, was not teratogenic in rabbits and rats at oral doses of 3.6 mg/kg/day and 10 mg/kg/day, respectively. These doses are approximately 100 times and 250 times higher respectively than the maximum recommended human topical ophthalmic daily dose of 2 mg (5 mg/mL x 0.05 mL/drop, x 4 drops x 2 eyes) to affected eyes on a mg/kg basis. Additionally, when administered to rats after Day 17 of gestation at oral doses up to 1.5 mg/kg/day (approximately 40 times the typical human topical ophthalmic daily dose), ketorolac tromethamine resulted in dystocia and increased pup mortality. There are no adequate and well-controlled studies in pregnant women. Ketorolac tromethamine ophthalmic solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.  
Nonteratogenic Effects: Because of the known effects of prostaglandin-inhibiting drugs on the fetal cardiovascular system (closure of the ductus arteriosus), the use of ketorolac tromethamine ophthalmic solution during late pregnancy should be avoided.
A total of 72 subjects will be enrolled. Specifically, a sufficient number of adults 18 years and older will be screened until 36 healthy (PPC-A) subjects and 36 subjects with severe periodontal disease (PPC-G) will be enrolled. Eligibility for study participation will be determined during the screening session. Barring dropout, subject participation will include 1 to 8 visits lasting over a maximum period of 42 days. The last 3 visits (visit 5-8) will depend on the individual need of the subject for providing SRP. Clinical data and medical history data will be collected at the screening visit to ascertain eligibility. All subjects will have dental plaque and a gingival biopsy collected at baseline. Enrolled subjects will be included in an experimental gingivitis model Stent-Induced Biofilm Overgrowth (SIBO) for 21 days. Individuals will return for safety checks every week during the 21-day period. At 21-days, plaque samples and a gingival biopsy will be collected. For diseased individuals SRP will initiate during the 21-day visit at the SIBO quadrant. Visit 6 (28 days) will include the post-biopsy follow up, prophylaxis (for healthy individuals) and SRP (diseased individuals). Subjects receiving SRP may have 2 additional visits (visit 7 at day 35 and visit 8 at day 42) for completing the SRP of all quadrants and will be dependent on individual need. Medical histories, demographics, height and weight, clinical and biological data described above will be recorded and stored on a secure server located at the University of North Carolina. Each participant enrolled into the study will have a unique identification number that has been stripped of any information that could be used by non-study members to identify the subject.
BACKGROUND: Observational studies and meta-analyses have indicated associations between blood lipid profiles and asthma. However, the causal association is unknown. Therefore, this study investigated the causal relationship between blood lipid profiles and asthma using bidirectional Mendelian randomization analysis.
METHODS AND MATERIALS: Our analyses were performed using individual data from the Taiwan Biobank and summary statistics from the Asian Genetic Epidemiology Network (AGEN). The causal estimates between all genetic variants, exposures of interest and asthma were calculated using an inverse-variance weighted method based on Taiwan Biobank data from 24,853 participants (mean age, 48.8 years; 49.8% women). Sensitivity analyses, including the weighted median, MR Egger regression, MR-PRESSO, mode-based estimate, contamination mixture methods, and leave-one-out analysis, were applied to validate the results and detect pleiotropy.
RESULTS: In the inverse-variance weighted (IVW) analyses, we found evidence of a significant causal effect of an increased level of low-density lipoprotein cholesterol on asthma risk (βIVW = 1.338, p = 0.001). A genetically decreased level of high-density lipoprotein cholesterol was also associated with asthma risk (βIVW = -0.338, p = 0.01). We also found that an increased level of total cholesterol was associated with an increased risk of asthma (βIVW = 1.343, p = 0.001). Several sensitivity analyses generated consistent findings. We did not find evidence to support the causality between asthma and blood lipid profiles in either direction.
CONCLUSION: Our results supported the causal relationship between higher levels of LDL cholesterol and total cholesterol and lower levels of HDL cholesterol with an increased risk of asthma.
An experimental group (GE): that after an initial evaluation will be subjected to a hypopressive abdominal gymnastics program, for 12 weeks with 2 weekly sessions (Tuesday and Thursday, controlling adherence to the sessions through attendance), with a duration of 45 min per session. Once the intervention is finished, you will be subjected to a final evaluation to see if there is a difference or not with the results obtained at the beginning.
In this study, 68 nursing students were randomly assigned to the acupressure and placebo (sham) acupressure groups. In the acupressure group (n=34), compression was applied to the 7th point of the heart meridian (HT7), the 4th point of the large intestine meridian (LI4), the 36th point of the stomach meridian (ST36), and the 6th point of the spleen meridian (SP6). Depending on the preparation and compression time at each point, the session duration of each student lasted an average of 20 minutes. In the sham group (n=34), pressure was applied approximately 1-1.5 cm away from the HT7, LI4, ST36, SP6 points. In the sham group, the acupressure application time lasted for an average of 20 minutes. At the end of the application, after the data collection process was completed, the sham group was taught the correct acupuncture points. Students applied acupressure three times a week for a total of 12 sessions for four weeks. Data were collected before and four weeks after the application in the acupressure and sham acupressure groups.